Millions of US men and women undergo screening for early cancer detection every year. Overdiagnosis, or the detection by screening of cases that would never become clinically diagnosed, is now recognized as the greatest potential harm of screening. This presents an especially difficult clinical dilemma in breast cancer, where screening detects many in-situ tumors, and in prostate cancer, where latent cases are highly prevalent in older age groups. Overdiagnosed cases cannot be helped by treatment and overtreatment of these cases carries a high price in terms of patient morbidity and economic costs. Knowledge about overdiagnosis is critical for well-formed screening policies and for well-informed patient decision making. However, overdiagnosis depends on screening practices and personal factors and many published studies are biased or do not apply to populations that differ from those used for estimation. The objective of this work is to advance knowledge about how to validly estimate overdiagnosis and to provide concrete information about overdiagnosis associated with specific cancer screening settings so as to inform screening policy development and clinical decision making. In our first aim we will conduct a simulation study to identify acceptable approaches and key characteristics of valid overdiagnosis studies. Lessons from this aim will be applied in our second aim, which will adapt established population models to estimate overdiagnosis rates associated with breast and prostate cancer screening under different screening policies and for different population subgroups defined by patient and tumor characteristics. These estimates will be made available to policy makers and clinicians via our third aim, which will develop online calculators to present relevant and useful information about overdiagnosis to these groups. Our study team of statisticians, breast and prostate cancer modelers and clinicians includes experts in simulation modeling, prominent clinical researchers and leaders in policy development for breast and prostate cancer screening. This work will move the field forward to a point of greater consensus about how to estimate overdiagnosis and what to tell policy makers and clinicians who have been tasked with shared and informed decision making. The knowledge generated by this application will lead to sound screening policies and better- informed clinical decisions and should provide a valuable quantitative tool in the ongoing battle to improve the balance of benefit and harm associated with cancer screening.
Overdiagnosis is what happens when people undergoing cancer screening are diagnosed with cancers that would never have progressed to cause problems or symptoms in their lifetimes. Patients with overdiagnosed cancers don't need treatment but most of them get it anyway. People are uncertain about the fraction of cancer cases that are overdiagnosed, but if they knew it, this information could help them make better medical decisions. This study will reduce confusion about overdiagnosis, produce new estimates of the chance of overdiagnosis in breast and prostate cancer , and develop a website that will provide this information to policy makers and doctors who can use it to help their patients make well informed decisions about whether different screening and/ treatment approaches are right for them.
|Shen, Yu; Dong, Wenli; Gulati, Roman et al. (2018) Estimating the frequency of indolent breast cancer in screening trials. Stat Methods Med Res :962280217754232|
|Gulati, Roman; Etzioni, Ruth (2017) A Matched Cohort Analysis of Prostate Cancer Screening in Younger Men in Sweden. Eur Urol 71:53-54|
|Lee, Christoph I; Etzioni, Ruth (2017) Missteps in Current Estimates of Cancer Overdiagnosis. Acad Radiol 24:226-229|
|Duffy, Stephen W; Etzioni, Ruth; Sasieni, Peter (2017) Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality. Evid Based Med 22:76|
|Gulati, Roman; Feuer, Eric J; Etzioni, Ruth (2016) Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies. Am J Epidemiol 184:140-7|
|Etzioni, Ruth; Gulati, Roman (2016) Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them. J Natl Cancer Inst 108:|
|Birnbaum, Jeanette; Gadi, Vijayakrishna K; Markowitz, Elan et al. (2016) The Effect of Treatment Advances on the Mortality Results of Breast Cancer Screening Trials: A Microsimulation Model. Ann Intern Med 164:236-43|
|Etzioni, Ruth; Gulati, Roman (2016) Active Surveillance for Ductal Carcinoma in Situ: Shining Light Into the Modeling Abyss. J Natl Cancer Inst 108:|